

## Pneumolysin Mediates Platelet Activation In Vitro

Nel, Jan Gert; Durandt, Chrisna; Mitchell, Timothy J; Feldman, Charles; Anderson, Ronald; Tintinger, Gregory R

DOI:

[10.1007/s00408-016-9900-5](https://doi.org/10.1007/s00408-016-9900-5)

License:

None: All rights reserved

*Document Version*

Peer reviewed version

*Citation for published version (Harvard):*

Nel, JG, Durandt, C, Mitchell, TJ, Feldman, C, Anderson, R & Tintinger, GR 2016, 'Pneumolysin Mediates Platelet Activation In Vitro', *Lung*, pp. 1-5. <https://doi.org/10.1007/s00408-016-9900-5>

[Link to publication on Research at Birmingham portal](#)

### **Publisher Rights Statement:**

The final publication is available at Springer via <http://dx.doi.org/10.1007/s00408-016-9900-5>

Checked 11/8/2016

### **General rights**

Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes permitted by law.

- Users may freely distribute the URL that is used to identify this publication.
- Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private study or non-commercial research.
- User may use extracts from the document in line with the concept of 'fair dealing' under the Copyright, Designs and Patents Act 1988 (?)
- Users may not further distribute the material nor use it for the purposes of commercial gain.

Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.

When citing, please reference the published version.

### **Take down policy**

While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been uploaded in error or has been deemed to be commercially or otherwise sensitive.

If you believe that this is the case for this document, please contact [UBIRA@lists.bham.ac.uk](mailto:UBIRA@lists.bham.ac.uk) providing details and we will remove access to the work immediately and investigate.

## **Pneumolysin mediates platelet activation *in vitro***

Jan Gert Nel,<sup>1</sup> Chrisna Durandt,<sup>2</sup> Timothy J. Mitchell,<sup>4</sup> Charles Feldman,<sup>5</sup> Ronald Anderson<sup>2</sup> , Gregory R. Tintinger <sup>3</sup>

<sup>1</sup>*Department of Haematology, Faculty of Health Sciences, University of Pretoria and Tshwane Academic Division of the National Health Laboratory Service, Pretoria, South Africa.*

<sup>2</sup>*Institute for Cellular and Molecular Medicine, and SAMRC Extramural Unit for Stem Cell Research and Therapy, Department of Immunology, Faculty of Health Sciences, University of Pretoria, Pretoria, South Africa*

<sup>3</sup>*Department of Internal Medicine, Faculty of Health Sciences, University of Pretoria, Pretoria, South Africa.*

<sup>4</sup>*Institute of Microbiology and Infection, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom.*

<sup>5</sup>*Division of Pulmonology, Department of Internal Medicine, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg and Charlotte Maxeke Academic Hospital, Johannesburg, South Africa.*

Short title: Pneumolysin-induces platelet activation

Correspondence:	Dr J.G. Nel Dept. Haematology PO Box 2034 Pretoria 0001 South Africa
e-mail:	<a href="mailto:jan.nel@up.ac.za">jan.nel@up.ac.za</a>
telephone:	+27-12-319-2641
telefax:	+27-12-323-0732

## Abstract

This study has explored the role of the pneumococcal toxin, pneumolysin (Ply), in activating human platelets. Following exposure to Ply [10–80 nanograms (ng)/ml], platelet activation and cytosolic  $\text{Ca}^{2+}$  concentrations were measured flow cytometrically according to the level of expression of CD62P (P-selectin) and spectrofluorimetrically respectively. Exposure to Ply resulted in marked upregulation of expression of platelet CD62P, achieving statistical significance at concentrations of 40 ng/ml and higher ( $p < 0.05$ ), in the setting of increased influx of  $\text{Ca}^{2+}$ . These potentially pro-thrombotic actions of Ply were attenuated by depletion of  $\text{Ca}^{2+}$  from the extracellular medium, or by exposure of the cells to a pneumolysoid devoid of pore-forming activity. These findings are consistent with a mechanism of Ply-mediated platelet activation involving sub-lytic pore formation,  $\text{Ca}^{2+}$  influx, and mobilization of CD62P-expressing  $\alpha$ -granules, which, if operative *in vivo*, may contribute to the pathogenesis of associated acute lung and myocardial injury during invasive pneumococcal disease.

**Keywords:** calcium, CD62P, community-acquired pneumonia, pneumococcus, P-selectin, *Streptococcus pneumoniae*

## Introduction

Despite significant advances in diagnosis, care and therapy, bacterial community-acquired pneumonia (CAP), of which *Streptococcus pneumoniae* (also known as the pneumococcus) is the major causative pathogen, continues to carry an unacceptably high mortality rate ranging from 5-50% [1]. Acute lung injury and multi-organ dysfunction syndrome, as well as acute cardiac events mostly occurring early in the course of CAP, have been identified as being significant contributors to mortality [1-7]. In the case of pneumococcal CAP, an increasing body of evidence, derived from both clinical and experimental studies, has implicated the major cytolytic, cholesterol-binding, pore-forming protein toxin, pneumolysin (Ply), in the pathogenesis of associated adverse pulmonary and cardiovascular events [8-13]. Although these harmful activities of Ply have been attributed to direct pulmonary and cardiac toxicity, it is noteworthy that Ply also possesses pro-inflammatory activities [14]. These are evident at lower, sub-lytic concentrations of the toxin and may also contribute to the pathogenesis of acute lung and cardiac injury in CAP.

Importantly, platelets are now recognized to be key players in orchestrating inflammatory responses [15], with platelet activation seemingly associated with acute lung injury in the experimental setting [9] and with myocardial infarction, worsening heart failure or arrhythmias in the clinical setting of invasive pneumococcal disease [16]. To our knowledge, however, only one previous study has addressed the direct involvement of Ply in mediating platelet activation, documenting aggregation of these cells following exposure to very high concentrations of the toxin, but without characterizing the mediators and mechanisms involved [17].

In the current study, we report on the effects of brief exposure of human platelets to Ply, at concentrations representative of severe pneumococcal disease [18], on expression of CD62P (P-selectin), as well as on influx of extracellular  $\text{Ca}^{2+}$ , an event which precedes and is a prerequisite for platelet activation. In this context, CD62P is widely recognized as being the major platelet-derived mediator of homotypic as well as heterotypic aggregation, the latter involving neutrophils and endothelial cells, activities which are both pro-inflammatory and pro-thrombotic [16,19].

## Materials and Methods

Permission to draw blood from healthy, adult human volunteers was granted by the Research Ethics Committee, Faculty of Health Sciences, University of Pretoria.

Recombinant Ply and the pneumolysoid, delta6Ply, attenuated in respect of pore-forming activity, were prepared as described previously [20, 21]. The possible influence of contaminating endotoxin was excluded in both Ply preparations using the Endosafe<sup>®</sup>-PTS<sup>™</sup> system (Charles River Laboratories, Wilmington, MA, USA) which is based on the *Limulus* amoebocyte lysate kinetic chromogenic method. Both active Ply and delta6Ply contained <1 endotoxin unit (EU)/microgram of protein after purification (1 EU is the lower limit of detection).

Unless stated otherwise all other chemicals and reagents were purchased from the Sigma Chemical Co., St Louis, MO., USA.

To prepare platelet-rich plasma (PRP), blood (anti-coagulated with 5 units/ml preservative-free heparin) was centrifuged at 1,000 rpm for 10 min at room temperature within 15 min of venepuncture and used immediately. PRP (10 µl) in a final volume of 1 ml Hanks' balanced salt solution (HBSS, indicator-free, 1.25 mM calcium, pH 7.4) was incubated for 5 min at 37°C after which one of the following was added: i) HBSS (control); ii) recombinant, endotoxin-free Ply (10, 20, 40, 80 ng/ml); iii) Ply (40 ng/ml) in Ca<sup>2+</sup>-free HBSS; iv) inactive, recombinant delta6Ply (80 ng/ml); v) the conventional platelet activator, adenosine diphosphate (ADP, 100 mM) as a positive control system; or vi) platelet-activating factor (PAF, 400 nM) as an additional positive control system. The platelets were then incubated for a further 5 min period after which flow cytometric analyses were performed to determine CD62P expression.

The platelet suspensions (median concentration  $3.2 \times 10^6$ /ml, range 2.2 to  $4.4 \times 10^6$ /ml) were stained with 5 µl mouse anti-human CD42a-PE-labelled (Beckman Coulter, Miami, USA) and 5 µl mouse anti-human CD62P-FITC-labelled (Becton Dickinson, Franklin Lakes, USA) monoclonal antibodies to detect the total and

activated platelet populations respectively. After 15 minutes of incubation in the dark, the samples were analysed on a Gallios flow cytometer (Beckman Coulter) and the results expressed as the percentage of activated platelets with 50,000 cells interrogated during each measurement.

The  $\text{Ca}^{2+}$ , cell-permeant, fluorescent probe, fura-2/AM, was used to measure alterations in platelet cytosolic  $\text{Ca}^{2+}$  following exposure of the cells to Ply. Briefly, platelet-rich plasma, prepared as described above, was incubated with fura-2/AM (4  $\mu\text{M}$ ) for 45 min at  $37^\circ$ , and washed in PBS with ethylene glycol tetraacetic acid (EGTA, 3 mM). The platelets were resuspended in HBSS containing 0.1% bovine serum albumin and held at room temperature until used.

The fura-2-loaded cells ( $1-2 \times 10^7/\text{ml}$ ) were preincubated for 5 min at  $37^\circ\text{C}$ , after which they were transferred to disposable reaction cuvettes, which were maintained at  $37^\circ\text{C}$  in a Hitachi 650 10S fluorescence spectrophotometer with excitation and emission wavelengths set at 340 and 500 nm respectively. After a stable baseline was obtained ( $\pm 1$  min), Ply (40 and 80 ng/ml) in the presence or absence of EGTA (3 mM), the pneumolysoid, delta6Ply, or ADP (100  $\mu\text{M}$ ), was added to the platelet suspension and the subsequent alterations in fura-2 fluorescence monitored over a 10 min time period.

## **Expression and statistical analysis of results**

The results of the flow cytometric measurement of CD62P are expressed as the median values with interquartile ranges (10 separate experiments using blood from 5 different donors). Statistical analyses were performed using GraphPad Prism 5 (GraphPad Software, San Diego, USA) using a one-way ANOVA with a Bonferroni correction for multiple comparisons. The results of the experiments designed to measure alterations in platelet cytosolic  $\text{Ca}^{2+}$  are shown as the individual traces from a single representative experiment (6 in the series using cells from 3 separate donors).

## Results

As shown in Figure 1, exposure of platelets to Ply caused a dose-related increase in the expression of CD62P, which achieved statistical significance at concentrations of 40 ng/ml and higher of the toxin ( $P < 0.05$ ), reaching levels comparable to those observed with PAF, but less than that with ADP. These effects of Ply were partly attenuated by depletion of  $\text{Ca}^{2+}$  from the cell-suspending medium, while the pneumolysoid, delta6Ply, was relatively ineffective.

The effects of exposure of platelets to Ply on cytosolic  $\text{Ca}^{2+}$  concentrations are shown in Figure 2. Treatment of platelets with Ply at concentrations of 40 or 80 ng/ml was accompanied by influx of  $\text{Ca}^{2+}$ , which following a short lag period, increased from basal levels of 29 (IQR= 23-37) nM to peak concentrations of 84 (IQR= 68-100) and 146 (IQR= 120-159) nM, respectively ( $P < 0.05$  for comparison of the basal values with the corresponding peak values following addition of Ply). The peak cytosolic  $\text{Ca}^{2+}$  concentrations did not decline for the full duration that fluorescence intensity was monitored. Inclusion of EGTA in the cell-suspending medium abolished the Ply-mediated influx of  $\text{Ca}^{2+}$ , while the pneumolysoid, delta6Ply, was ineffective. An abrupt increase in fluorescence intensity which rapidly declined to basal levels was observed in the presence of ADP, indicative of a transient increase in cytosolic  $\text{Ca}^{2+}$  concentrations (results not shown).

## Discussion

These findings demonstrate that exposure of human platelets to Ply at concentrations ranging from 40–80 ng/ml *in vitro* results in significant upregulation of expression of CD62P, a marker of platelet activation. These concentrations of Ply are of probable pathologic relevance being somewhat lower than those measured in the cerebrospinal fluid of patients with confirmed pneumococcal meningitis [18]. The attenuation of Ply-mediated platelet activation observed when the cells were suspended in  $\text{Ca}^{2+}$ -free medium, or following exposure to the pneumolysoid, delta6Ply, are consistent with the requirement for pore formation and influx of

extracellular  $\text{Ca}^{2+}$  in upregulation of expression of CD62P. This contention is strongly supported by the finding that exposure of platelets to Ply, but not to delta6Ply, resulted in significant influx of  $\text{Ca}^{2+}$  which was abolished by depletion of  $\text{Ca}^{2+}$  from the cell-suspending medium. Unlike the immediate increases in cytosolic  $\text{Ca}^{2+}$  which were evident following receptor-mediated activation of platelets with ADP, Ply-mediated influx of the cation occurred after a short lag phase, reaching peak responses that remained elevated and did not decline to basal levels in keeping with the pore-forming mechanism of activity of Ply.

This study has focused on CD62P because upregulation of expression of this adhesion molecule on platelets is increasingly recognized as being a key mediator of inflammatory events, directing neutrophil trafficking and activation [15]. More recently, CD62P has also been reported to be the primary mediator of heterotypic platelet-neutrophil aggregation [19], a central event in the pathogenesis of arterial thrombogenesis [22]. The mechanism of Ply-mediated platelet activation appears to involve sublytic pore formation and influx of  $\text{Ca}^{2+}$ , resulting in mobilization of CD62P-expressing  $\alpha$ -granules.

Notwithstanding the previously documented direct, cytotoxic activities of Ply [8-13], the results of the current study are consistent with the existence of an additional potential mechanism of toxin-mediated acute adverse pulmonary and cardiac events, *viz.* platelet activation, which remains to be established in the clinical setting. Nonetheless, these novel findings raise the important issue of the therapeutic potential of Ply- and platelet-directed therapies in the prevention or attenuation of pneumococcal CAP-related cardiac morbidity and mortality.



## References

1. Welte T (2012) Risk factors and severity scores in hospitalized patients with community-acquired pneumonia: prediction of severity and mortality. *Eur J Clin Microbiol Infect Dis* 31(1):33–47. doi: 10.1007/s10096-011-1272-4
2. Steel HC, Cockeran R, Anderson R et al (2013) Overview of community-acquired pneumonia and the role of inflammatory mechanisms in the immunopathogenesis of severe pneumococcal disease. *Mediators Inflamm* 2013:490346. doi: 10.1155/2013/490346
3. Bong Y, Shin SG, Koh SH et al (2015) Interleukin-1 $\beta$  participates in the development of pneumococcal acute lung injury and death by promoting alveolar microvascular leakage. *J Bacteriol Virol* 45(2):93–103. doi: 10.4167/jbv.2015.45.2.93
4. Musher DM, Rueda AM, Kaka AS et al (2007) The association between pneumococcal pneumonia and acute cardiac events. *Clin Infect Dis* 45(2):158–165. doi: 10.1086/518849
5. Corrales-Medina VF, Serpa J, Rueda AM et al (2009) Acute bacterial pneumonia is associated with the occurrence of acute coronary syndromes. *Medicine (Baltimore)* 88(3):154–159. doi: 10.1097/MD.0b013e3181a692f0
6. Corrales-Medina VF, Musher DM, Wells GA et al (2012) Cardiac complications in patients with community-acquired pneumonia: incidence, timing, risk factors, and association with short-term mortality. *Circulation* 125(6):773–781. doi: 10.1161/CIRCULATIONAHA.111.040766
7. Aliberti S, Ramirez JA (2014) Cardiac diseases complicating community-acquired pneumonia. *Curr Opin Infect Dis* 27(3):295–301. doi: 10.1097/QCO.0000000000000055
8. Witzenrath M, Gutbier B, Hocke AC et al (2006) Role of pneumolysin for the development of acute lung injury in pneumococcal pneumonia. *Crit Care Med* 34(7):1947–1954. doi: 10.1097/01.CCM.0000220496.48295.A9
9. Witzenrath M, Gutbier B, Owen JS et al (2007) Role of platelet-activating factor in pneumolysin-induced acute lung injury. *Crit Care Med* 35(7):1756–1762. doi: 10.1097/01.CCM0000269212.84709.23

10. García-Suárez Mdel M, Flórez N, Astudillo A et al (2007) The role of pneumolysin in mediating lung damage in a lethal pneumococcal pneumonia murine model. *Respir Res* 8(1):3. doi: 10.1186/1465-9921-8-3
11. Rosch JW, Boyd AR, Hinojosa E et al (2010) Statins protect against fulminant pneumococcal infection and cytotoxin toxicity in a mouse model of sickle cell disease. *J Clin Invest* 120(2):627–635. doi: 10.1172/JCI39843
12. Brown AO, Mann B, Gao G et al (2014) *Streptococcus pneumoniae* translocates into the myocardium and forms unique microlesions that disrupt cardiac function. *PLoS Pathog* 10(9):e1004383. doi: 10.1371/journal.ppat.1004383
13. Alhamdi Y, Neill DR, Abrams ST et al (2015) Circulating pneumolysin is a potent inducer of cardiac injury during pneumococcal infection. *PLoS Pathog* 11(5):e1004836. doi: 10.1371/journal.ppat.1004836
14. Cockeran R, Steel HC, Theron AJ et al (2011) Characterization of the interactions of the pneumolysin, Delta6 PLY, with human neutrophils *in vitro*. *Vaccine* 29(48):8780–8782. doi: 10.1016/j.vaccine.2011.09.080
15. Sreeramkumar V, Adrover JM, Ballesteros I et al (2014) Neutrophils scan for activated platelets to initiate inflammation. *Science* 346(6214):1234–1238. doi: 10.1126/science.1256478
16. Cangemi R, Casciaro M, Rossi E et al (2014) Platelet activation is associated with myocardial infarction in patients with pneumonia. *J Am Coll Cardiol* 64(18):1917–1925. doi: 10.1016/j.jacc.2014.07.985
17. Ohkuni H, Nagamune H, Ozaki N et al (2011) Characterization of recombinant *Streptococcus mitis*-derived human platelet aggregation factor. *APMIS* 120(1):56–71. doi: 10.1111/j.1600-0463.2011.02813.x
18. Wall EC, Gordon SB, Hussain S et al (2012) Persistence of pneumolysin in the cerebrospinal fluid of patients with pneumococcal meningitis is associated with mortality. *Clin Infect Dis* 54(5):701–705. doi: 10.1093/cid/cir926
19. Mauler M, Seyfert J, Haenel D et al (2015) Platelet-neutrophil complex formation—a detailed in vitro analysis of murine and human blood samples. *J Leukoc Biol* 2015 Nov 17 [Epub ahead of print]. doi: 10.1189/jlb.3TA0315-082R
20. Saunders FK, Mitchell TJ, Walker JA et al (1989) Pneumolysin, the thiol-activated toxin of *Streptococcus pneumoniae*, does not require a thiol group for *in vitro* activity. *Infect Immun* 57(8):2547–2552

21. Kirkham LA, Kerr AR, Douce GR et al (2006) Construction and immunological characterization of a novel nontoxic protective pneumolysin mutant for use in future pneumococcal vaccines. *Infect Immun* 74(1):586–593. doi: 10.1128/IAI.74.1.586-593.2006
22. Yokoyama S, Ikeda H, Haramaki N et al (2005) Platelet P-selectin plays an important role in arterial thrombogenesis by forming large stable platelet-leukocyte aggregates. *J Am Coll Cardiol* 45(8):1280–1286. doi: 10.1016/j.jacc.2004.12.071





Figure 2



### Figure Legends

Figure 1: Box - and – whisker plots showing the effects on platelet activation, measured according to the percentage of cells expressing CD62P, of: i) pneumolysin (Ply) at concentrations of 10, 20, 40, 80 ng/ml; ii) Ply (40 ng/ml) in  $\text{Ca}^{2+}$ -free medium (Ca f); iii) delta6Ply (80 ng/ml); and iv) ADP (100  $\mu\text{M}$ ) and PAF (400 nM) as positive controls. The results of 10 experiments are expressed as the median values with interquartile ranges (25-75%).

\* $P < 0.05$

Figure 2: The effects of pneumolysin ( — ) at a concentration of 40 ng/ml only on the influx of  $\text{Ca}^{2+}$  into platelets measured according to an increase in fluorescence intensity of intracellular fura-2/AM are shown in A; those of Ply at 80 ng/ml in the absence ( — ) or presence of EGTA (— — —) are shown in B. The effects of active Ply ( — ) in comparison with those of the pneumolysoid delta6Ply (·····) at a concentration of 80 ng/ml are shown in C. Ply and delta6Ply were added as indicated by the arrow. These traces are from a single representative experiment (6 in the series).